person · Reporting owner

MIZELL STEVEN

Disclosed activity across 6 companies

Tapewire entity: 11446
SEC CIK: 0001189403

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allegion plcALLE · Entity 3420	Director	August 28, 2026	August 31, 2026
GRAIL, Inc.GRAL · Entity 4122	Director	July 15, 2026	July 16, 2026
GROUP 1 AUTOMOTIVE INCGPI · Entity 1789	Director	January 02, 2026	January 06, 2026
Merck & Co., Inc.MRK · Entity 2807	EVP, Chief HR Officer	February 02, 2024	February 02, 2024
OSHKOSH CORPOSK · Entity 3573	Director	November 19, 2018	November 21, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allegion plc

Report date August 28, 2026 · Filed August 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	5,899	Reported balance After 2026-08-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-28 · Purchase · Acquired 170 · Balance 5,899 F1: Includes shares acquired through a dividend reinvestment plan since the Reporting Person's last Form 4 filing.

Filing footnotes · ownership attribution and instrument terms

F1: Includes shares acquired through a dividend reinvestment plan since the Reporting Person's last Form 4 filing.

GRAIL, Inc.

Report date July 15, 2026 · Filed July 16, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	42,830	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 268 · Balance 42,830 F1: Represents 268 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents 268 deferred stock units granted to Mr. Mizell under our deferred stock program and 2024 Equity Incentive Plan in lieu of $19,945.21 of cash fees payable to Mr. Mizell for his service as a director, based on a price per share of $74.36, which was the closing price per share of the Company's common stock on July 15, 2026. The awards will vest immediately upon grant date.

GROUP 1 AUTOMOTIVE INC

Report date January 02, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	583	Reported balance After 2026-01-02 transaction · row 1 1 source row Row 1 · 2026-01-02 · Grant · Acquired 575 · Balance 583

Merck & Co., Inc.

Report date February 02, 2024 · Filed February 02, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,619.145	Ending reported balance After 2024-02-02 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2024-02-02 · Exercise / conversion · Acquired 824 · Balance 42,143.145 Row 2 · 2024-02-02 · Exercise / conversion · Acquired 32,170 · Balance 74,313.145 Row 3 · 2024-02-02 · Sale · Disposed 50,694 · Balance 23,619.145 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.71 · Expires 2028-10-29	Direct	0	Reported balance After 2024-02-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-02 · Exercise / conversion · Disposed 824 · Balance 0 F2: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $73.73 · Expires 2031-05-03	Direct	22,088	Reported balance After 2024-02-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-02 · Exercise / conversion · Disposed 32,170 · Balance 22,088 F3: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.4300 to $126.9000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021.

F3: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.

OSHKOSH CORP

Report date November 19, 2018 · Filed November 21, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,660.31	Reported balance After 2018-11-19 transaction · row 1 1 source row Row 1 · 2018-11-19 · Grant · Acquired 47.34 · Balance 11,660.31 F1: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers.

Filing footnotes · ownership attribution and instrument terms

F1: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MONSANTO CO /NEW/

Report date June 07, 2018 · Filed June 07, 2018

Section 16 reporting ended · disclosed 2018-06-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-06-07 · Disposition to issuer · Disposed 62 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2018-06-07 · Disposition to issuer · Disposed 48,581 · Balance 0 F4: Represents restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-06-07 transaction · row 4 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 4 · 2018-06-07 · Disposition to issuer · Disposed 19,787 · Balance 0 F5: Represents performance-based restricted stock units. F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Common StockSEC Table I · non-derivative	IndirectBy 401(k) Plan	Reported balance After 2018-06-07 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-06-07 · Disposition to issuer · Disposed 1,024 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.71	Direct	Reported balance After 2018-06-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-06-07 · Disposition to issuer · Disposed 7 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.79	Direct	Reported balance After 2018-06-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-06-07 · Disposition to issuer · Disposed 70 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.48	Direct	Reported balance After 2018-06-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-06-07 · Disposition to issuer · Disposed 91 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.05	Direct	Reported balance After 2018-06-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-06-07 · Disposition to issuer · Disposed 80 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.82	Direct	Reported balance After 2018-06-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-06-07 · Disposition to issuer · Disposed 5,764 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $91.34	Direct	Reported balance After 2018-06-07 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-06-07 · Disposition to issuer · Disposed 7,234 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.
Deferred Payment Plan Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-06-07 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2018-06-07 · Disposition to issuer · Disposed 1,926 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.
Phantom Share UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-06-07 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2018-06-07 · Disposition to issuer · Disposed 16,473 · Balance 0 F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration").

F2: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate.

F3: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest.

F4: Represents restricted stock units.

F5: Represents performance-based restricted stock units.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 02, 2023 Filed May 4, 2023 21:40 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (Right to Buy) · Derivative	29,046	$0.00 Strike: $117.89	$0.00	Disclosure SEC source: 0001127602-23-014539 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,046 Underlying: Common Stock · 29,046 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document
February 13, 2023 Filed Feb 14, 2023 15:03 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	1,815	$109.10	$198,017.04	Disclosure SEC source: 0001127602-23-005037 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,085.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.1000 to $109.1050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
February 09, 2023 Filed Feb 10, 2023 16:28 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	5,000	$107.00	$535,006.50	Disclosure SEC source: 0001127602-23-004321 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,900.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.0000 to $107.0300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
February 06, 2023 Filed Feb 8, 2023 15:27 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	4,436	$104.25	$462,473.41	Disclosure SEC source: 0001127602-23-003923 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,900.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.2350 to $104.2850, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Read SEC document
January 23, 2023 Filed Jan 25, 2023 22:14 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantCommon Stock	12,192	$109.88	$1,339,656.96	Disclosure SEC source: 0001127602-23-002241 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,336.145 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. Read SEC document
January 03, 2023 Filed Jan 5, 2023 22:53 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantRestricted Stock Units · Derivative	1,102	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-000984 · form4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,201 Underlying: Common Stock · 1,102 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the cash value of one share of Group 1 Automotive, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in Section 1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. F2 · derivative.expiration_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in Section 1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. Read SEC document
November 10, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $70.71	$0.00	Disclosure SEC source: 0001127602-22-025313 · form4.xml · derivative · entry 6 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 824 Underlying: Common Stock · 15,000 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
November 10, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	15,000	$101.42	$1,521,277.50	Disclosure SEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 4 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,144.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.4000 to $101.5300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
November 10, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	15,000	$0.00	$0.00	Disclosure SEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,144.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $70.71	$0.00	Disclosure SEC source: 0001127602-22-025313 · form4.xml · derivative · entry 5 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,824 Underlying: Common Stock · 20,000 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	20,000	$101.00	$2,020,000.00	Disclosure SEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,144.145 Read SEC document
November 08, 2022 Filed Nov 10, 2022 22:01 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	20,000	$0.00	$0.00	Disclosure SEC source: 0001127602-22-025313 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,144.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 28, 2022 Filed Nov 1, 2022 20:33 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $70.71	$0.00	Disclosure SEC source: 0001127602-22-024602 · form4.xml · derivative · entry 4 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,824 Underlying: Common Stock · 17,000 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The option vested and became exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. F3 · balance_after: Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document
October 28, 2022 Filed Nov 1, 2022 20:33 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	8,000	$98.84	$790,720.00	Disclosure SEC source: 0001127602-22-024602 · form4.xml · nonDerivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,144.145 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.8400 to $98.8450, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
October 28, 2022 Filed Nov 1, 2022 20:33 UTC	Merck & Co., Inc. MRK · Entity 2807	SaleCommon Stock	17,000	$100.00	$1,700,000.00	Disclosure SEC source: 0001127602-22-024602 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,144.145 Read SEC document
October 28, 2022 Filed Nov 1, 2022 20:33 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	17,000	$0.00	$0.00	Disclosure SEC source: 0001127602-22-024602 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,144.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 03, 2022 Filed Jun 7, 2022 20:23 UTC	Allegion plc ALLE · Entity 3420	Tax withholdingOrdinary Shares	241	$112.36	$27,078.76	Disclosure SEC source: 0001127602-22-016987 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,719 Read SEC document
June 02, 2022 Filed Jun 6, 2022 20:25 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,016	$0.00	$0.00	Disclosure SEC source: 0001127602-22-016879 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,960 F1 · shares: Restricted stock units that vest on June 2, 2023. F2 · balance_after: Includes acquisition of shares through a dividend reinvestment plan. Read SEC document
May 03, 2022 Filed May 5, 2022 21:13 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (Right to Buy) · Derivative	40,777	$0.00 Strike: $87.10	$0.00	Disclosure SEC source: 0001127602-22-013530 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,777 Underlying: Common Stock · 40,777 shares Expires 2032-05-02 F2 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document
February 24, 2022 Filed Feb 28, 2022 21:29 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantCommon Stock	14,571	$73.51	$1,071,114.21	Disclosure SEC source: 0001127602-22-007025 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,144.145 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
January 03, 2022 Filed Jan 5, 2022 16:19 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantRestricted Stock Units · Derivative	1,030	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-22-000757 · form4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099 Underlying: Common Stock · 1,030 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the cash value of one share of Group 1 Automotive, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in ?1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. F2 · derivative.expiration_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in ?1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. Read SEC document
October 30, 2021 Filed Nov 2, 2021 22:11 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionRestricted Stock Unit · Derivative	4,715	$0.00	$0.00	Disclosure SEC source: 0001127602-21-028163 · form4.xml · derivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,715 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F4 · derivative.exercise_date: The restricted stock units vested and were distributed in equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. F3 · derivative.underlying_shares: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. F3 · balance_after: Holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck time-based restricted stock unit awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. Read SEC document
October 30, 2021 Filed Nov 2, 2021 22:11 UTC	Merck & Co., Inc. MRK · Entity 2807	Tax withholdingCommon Stock	2,323	$88.05	$204,540.15	Disclosure SEC source: 0001127602-21-028163 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,573.145 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
October 30, 2021 Filed Nov 2, 2021 22:11 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	4,715	$88.05	$415,155.75	Disclosure SEC source: 0001127602-21-028163 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,896.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 03, 2021 Filed Jun 7, 2021 22:13 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	835	$0.00	$0.00	Disclosure SEC source: 0001127602-21-019391 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,934 F1 · shares: Restricted stock units that vest on June 3, 2022. Read SEC document
May 04, 2021 Filed May 6, 2021 20:53 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (Right to Buy) · Derivative	64,286	$0.00 Strike: $75.99	$0.00	Disclosure SEC source: 0001127602-21-015760 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,286 Underlying: Common Stock · 64,286 shares Expires 2031-05-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:29 UTC	GROUP 1 AUTOMOTIVE INC GPI · Entity 1789	GrantRestricted Stock Units · Derivative	1,069	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-21-008719 · form4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,069 Underlying: Common Stock · 1,069 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive the cash value of one share of Group 1 Automotive, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in ?1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. F2 · derivative.expiration_date: The restricted stock units settle on the date of the director's separation from service, as such term is defined in ?1.409A-1(h) under Title 26 of the Internal Revenue Code, and will be settled in a lump sum cash payment. Read SEC document
February 26, 2021 Filed Mar 2, 2021 16:54 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantCommon Stock	17,830	$72.62	$1,294,814.60	Disclosure SEC source: 0001127602-21-008581 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,181.145 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 10/30/18. Performance shares were paid out at 166 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2020. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
October 30, 2020 Filed Nov 3, 2020 21:44 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionRestricted Stock Unit · Derivative	4,574	$0.00	$0.00	Disclosure SEC source: 0001127602-20-028032 · form4.xml · derivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,575 Underlying: Common Stock · 4,574 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
October 30, 2020 Filed Nov 3, 2020 21:44 UTC	Merck & Co., Inc. MRK · Entity 2807	Tax withholdingCommon Stock	2,273	$75.89	$172,497.97	Disclosure SEC source: 0001127602-20-028032 · form4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,351.145 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document
October 30, 2020 Filed Nov 3, 2020 21:44 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	4,574	$75.89	$347,120.86	Disclosure SEC source: 0001127602-20-028032 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,624.145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 04, 2020 Filed Jun 8, 2020 20:13 UTC	Allegion plc ALLE · Entity 3420	GrantOrdinary Shares	1,099	$0.00	$0.00	Disclosure SEC source: 0001127602-20-019118 · form4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,099 F1 · shares: Restricted stock units that vest on June 4, 2021. Read SEC document
May 01, 2020 Filed May 5, 2020 20:49 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (Right to Buy) · Derivative	57,391	$0.00 Strike: $77.67	$0.00	Disclosure SEC source: 0001127602-20-015452 · form4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,391 Underlying: Common Stock · 57,391 shares Expires 2030-04-30 F2 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document
October 30, 2019 Filed Nov 1, 2019 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionRestricted Stock Unit · Derivative	4,574	$85.10	$389,247.40	Disclosure SEC source: 0001225208-19-014016 · doc4.xml · derivative · entry 3 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,149 Underlying: Common Stock · 4,574 shares Expires 2021-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
October 30, 2019 Filed Nov 1, 2019 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Tax withholdingCommon Stock	1,567	$85.10	$133,351.70	Disclosure SEC source: 0001225208-19-014016 · doc4.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007 Read SEC document
October 30, 2019 Filed Nov 1, 2019 21:07 UTC	Merck & Co., Inc. MRK · Entity 2807	Exercise / conversionCommon Stock	4,574	$0.00	$0.00	Disclosure SEC source: 0001225208-19-014016 · doc4.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 03, 2019 Filed May 7, 2019 23:39 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (right to buy) · Derivative	50,808	$0.00 Strike: $80.00	$0.00	Disclosure SEC source: 0001104659-19-027583 · a4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP,Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,808 Underlying: Common Stock · 50,808 shares Expires 2029-05-02 F1 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document
November 19, 2018 Filed Nov 21, 2018 16:58 UTC	OSHKOSH CORP OSK · Entity 3573	GrantCommon Stock	47.34	$66.09	$3,128.70	Disclosure SEC source: 0000775158-18-000151 · edgar.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,660.31 F1 · shares: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers. Read SEC document
November 15, 2018 Filed Nov 16, 2018 18:21 UTC	OSHKOSH CORP OSK · Entity 3573	GrantCommon Stock	282.88	$67.37	$19,057.63	Disclosure SEC source: 0000775158-18-000144 · edgar.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,612.97 F1 · shares: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the automatic purchase feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers. Read SEC document
October 30, 2018 Filed Nov 1, 2018 21:05 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantStock Option (right to buy) · Derivative	51,252	$0.00 Strike: $72.87	$0.00	Disclosure SEC source: 0001225208-18-015064 · doc4.xml · derivative · entry 2 MIZELL STEVEN · CIK 0001189403 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,252 Underlying: Common Stock · 51,252 shares Expires 2028-10-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
October 30, 2018 Filed Nov 1, 2018 21:05 UTC	Merck & Co., Inc. MRK · Entity 2807	GrantRestricted Stock Unit · Derivative	13,723	$0.00	$0.00	Disclosure SEC source: 0001225208-18-015064 · doc4.xml · derivative · entry 1 MIZELL STEVEN · CIK 0001189403 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,723 Underlying: Common Stock · 13,723 shares Expires 2021-10-30 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 10/30/2019, 10/30/2020 and 10/30/2021. Read SEC document
August 16, 2018 Filed Aug 17, 2018 17:57 UTC	OSHKOSH CORP OSK · Entity 3573	GrantCommon Stock	39.06	$69.23	$2,704.12	Disclosure SEC source: 0000775158-18-000099 · edgar.xml · nonDerivative · entry 2 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,330.09 F2 · shares: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the dividend reinvestment feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers. Read SEC document
August 15, 2018 Filed Aug 17, 2018 17:57 UTC	OSHKOSH CORP OSK · Entity 3573	GrantCommon Stock	280.59	$67.92	$19,057.67	Disclosure SEC source: 0000775158-18-000099 · edgar.xml · nonDerivative · entry 1 MIZELL STEVEN · CIK 0001189403 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,291.03 F1 · shares: Represents stock units payable in Oshkosh Corporation common stock acquired in accordance with the automatic purchase feature of the Oshkosh Corporation Deferred Compensation Plan for Directors and Executive Officers. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerPhantom Share Units · Derivative	16,473	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 12 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,473 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.exercise_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.expiration_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.expiration_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerDeferred Payment Plan Restricted Stock Unit · Derivative	1,926	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 11 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,926 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · price: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · price: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.exercise_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.exercise_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. F1 · derivative.expiration_date: Pursuant to the terms of and subject to certain exceptions set forth in the Agreement and Plan of Merger, dated as of September 14, 2016 (the "Merger Agreement"), by and among Bayer Aktiengesellschaft ("Bayer"), KWA Investment Co. ("Merger Sub") and Monsanto Company (the "Company"), each share of common stock of the Company and each time- or performance-vesting restricted stock unit of the Company outstanding immediately prior to the effective time of the merger (the "Effective Time") was automatically converted into the right to receive $128.00 in cash, without interest (the "Merger Consideration"). F2 · derivative.expiration_date: (Continued from Footnote 1) The Merger Consideration that is payable in respect of restricted stock units of the Company that were granted (a) prior to September 14, 2016 is fully vested as of the Effective Time or (b) after September 14, 2016 will vest based upon the vesting schedule applicable to the corresponding restricted stock units (subject to accelerated vesting in full upon a termination of employment without cause, for good reason or due to death, disability or retirement). Any Merger Consideration that is not paid at the Effective Time will begin accruing interest as of the Effective Time at the short-term federal rate. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerStock Option (Right to Buy) · Derivative	7,234	Not disclosed Strike: $91.34	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 10 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,234 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerStock Option (Right to Buy) · Derivative	5,764	Not disclosed Strike: $112.82	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 9 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,764 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerStock Option (Right to Buy) · Derivative	80	Not disclosed Strike: $106.05	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 8 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerStock Option (Right to Buy) · Derivative	91	Not disclosed Strike: $90.48	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 7 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. Read SEC document
June 07, 2018 Filed Jun 7, 2018 17:09 UTC	MONSANTO CO /NEW/ MON · Entity 165931	Disposition to issuerStock Option (Right to Buy) · Derivative	70	Not disclosed Strike: $74.79	Not disclosed	Disclosure SEC source: 0000899243-18-015517 · doc4.xml · derivative · entry 6 MIZELL STEVEN · CIK 0001189403 · EVP, Chief HR Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each option to purchase shares of common stock of the Company outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into the right to receive the Merger Consideration less the applicable exercise price of such option, without interest. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.